Mylan Loses Duragesic Case; Generic Launch Timing Dispute Moves To FDA
Executive Summary
The launch timing for the first generic version of Johnson & Johnson/Alza's Duragesic fentanyl patch will depend on FDA's decision about a six-month pediatric exclusivity extension for the product
You may also be interested in...
Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
FDA Decision On Mylan Duragesic ANDA Upheld By D.C. Court
FDA did not err in barring Mylan's transdermal fentanyl patch from coming to market until after Johnson & Johnson/Alza's pediatric exclusivity for Duragesic expires Jan. 23, a D.C. federal court said